Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 114, Issue 1, 2002, Pages 46-50

  Martí, Sylvia Bort ^a   Cichon, Sven ^a   Propping, Peter ^a   Nöthen, Markus ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Association study; Bipolar affective disorder; Glutamate receptors; Schizophrenia; Transmission disequilibrium test

Indexed keywords

METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 3;

BIPOLAR DISORDER; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENETICS; GERMANY; HUMAN; MALE; SCHIZOPHRENIA;

BIPOLAR DISORDER; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GERMANY; HUMANS; MALE; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 38149138747     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.1624     Document Type: Article

References (25)

1. Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. 1998. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 31(suppl 2):104-109.
2. American Psychiatric Association. 1987. Diagnostic and statistical manual of mental disorders, 3rd rev ed. Washington DC: American Psychiatric Association.
3. Aparicio-Legarza MI, Davis B, Hutson PH, Reynolds GP. 1998. Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients. Neurosci Lett 241:143-146. (Pubitemid 28114182)
4. Battaglia G, Monn JA, Schoepp DD. 1997. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett 229:161-164.
5. Blouin JL, Dombroski BA, Nath SK, Lasseter VK, Wolyniec PS, Nestadt G, Thornquist M, Ullrich G, McGrath J, Carlsson A. 1978. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135:165-173.
6. Budowle B, Chakraborty R, Giusti AM, Eisenberg AJ, Allen RC. 1991. Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE. Am J Hum Genet 48:137-144. (Pubitemid 21903036)
7. Cotman CW, Kahle JS, Miller SE, Ulas J, Bridges RJ. 1995. Excitatory amino acid neurotransmission. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press. p 75-85.
8. Coyle JT. 1996. The glutamatergic dyfunction hypothesis for schizophrenia. Harvard Rev Psychiatry 3:241-253.
9. Ekelund J, Lichtermann D, Hovatta I, Ellonen P, Suvisaari J, Terwilliger JD, Juvonen H, Varilo T, Arajarvi R, Kokko-Sahin ML, Lonnqvist J, Peltonen L. 2000. Genome-wide scan for schizophrenia in the Finnish population: evidence for a locus on chromosome 7q22. Hum Mol Genet 7:1049-1057. (Pubitemid 30216010)
10. Ellison G. 1995. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Brain Res Rev 20:250-267.
11. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
12. Lovinger DM, McCool BA. 1995. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. J Neurophysiol 73:1076-1083.
13. Luby ED, Cohen BD, Rosenbaum F, Gottlieb J, Kelley R. 1959. Study of a new schizophrenomimetic drug, Sernyl. Arch Neurol Psychiatry 81:363-369.
14. Mackay AV, Bird ED, Spokes EG, Rossor M, Iversen LL, Creese I, Snyder SH. 1980. Dopamine receptors and schizophrenia: drug effect or illness? Lancet 2:915-916.
15. Makoff A, Volpe F, Lelchuk R, Harrington K, Emson P. 1996. Molecular characterization and localization of human metabotropic glutamate receptor type 3. Brain Res Mol Brain Res 40:55-63. (Pubitemid 26241786)
16. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A. 1997. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141-150. (Pubitemid 27365955)
17. Manuzza S, Fyer AJ, Klein DF, Endicott J. 1986. Schedule for affective disorder and schizophrenia-Lifetime version (modified for the study of anxiety disorders): rationale and conceptual development. J Psychiatr Res 20:317-325. (Pubitemid 17200251)
18. Moghaddam B, Adams BW. 1998. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352. (Pubitemid 28406826)
19. Moghaddam B, Adams B, Verma A, Daly D. 1997. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927. (Pubitemid 27155025)
20. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. 1998. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res 56:207-217. (Pubitemid 28271678)
21. Paus S, Rietschel M, Albus M, Maier W, Propping P, Nöthen M. 1998. Systematic screening for mutations in the human NMDR1 gene in patients with schizophrenia. Am J Med Gen 81:519. (Pubitemid 128766206)
22. Pin JP, Duvoisin R. 1995. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34:1-26.
23. Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff JH. 2000. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry 47:22-28. (Pubitemid 30016076)
24. Risch N, Merikangas K. 1996. The future of genetic studies of complex human diseases. Science 273:1516-1517. (Pubitemid 26301653)
25. Scherer SW, Duvoisin RM, Kuhn R, Heng HH, Belloni E, Tsui. 1996. Localization of two metabotropic glutamate receptor genes, GRM3 and GRM8, to human chromosome 7q. Genomics 31:230-233.